NUWE Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

2.50M

+5.62%

-1.560

-91.56%

2.31M

-0.52%

-0.700

-97.58%

-0.590

-99.03%

Estimates Revision

The market is revising No Change the revenue expectations for Nuwellis, Inc. (NUWE) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -43.66%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-43.66%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast NUWE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUWE is 3.90 USD with a low forecast of 3.90 USD and a high forecast of 3.90 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

1 Hold

0 Sell

Hold

Current: 0.000

Low

3.90

Averages

3.90

High

3.90

Current: 0.000

Low

3.90

Averages

3.90

High

3.90

Roth Capital

Jonathan Aschoff

Buy

downgrade

$13 -> $11

2025-05-13

Reason

Roth Capital

Jonathan Aschoff

Price Target

$13 -> $11

2025-05-13

downgrade

Buy

Reason

Roth Capital analyst Jonathan Aschoff lowered the firm's price target on Nuwellis to $11 from $13 and keeps a Buy rating on the shares. While the company's Q1 revenue was down 18% quarter over quarter, pediatric utilization grew 38% year over year, the analyst tells investors in a research note. The firm believes that the four-fold increase in Aquadex Centers for Medicare & Medicaid Services reimbursement should support future revenue growth.

Valuation Metrics

The current forward P/E ratio for Nuwellis Inc (NUWE.O) is -0.56, compared to its 5-year average forward P/E of -0.72. For a more detailed relative valuation and DCF analysis to assess Nuwellis Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-0.72

Current PE

-0.56

Overvalued PE

-0.14

Undervalued PE

-1.30

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.20

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.56

Undervalued EV/EBITDA

-0.16

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.87

Current PS

0.34

Overvalued PS

1.75

Undervalued PS

-0.01

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

NUWE News & Events

Events Timeline

No data

News

3.5

01-06Globenewswire

Nuwellis Secures New Patent Enhancing Blood Filtration Safety Mechanisms

3.5

2025-12-09Globenewswire

Nuwellis Presents Aquadex Therapy Applications for Acute Kidney Injury at ASN Kidney Week

7.5

2025-12-04Globenewswire

Nuwellis Launches Aquadex Ultrafiltration Program at Leading Children's Hospital

People Also Watch

Frequently Asked Questions

What is Nuwellis Inc (NUWE) stock price today?

The current price of NUWE is 2 USD — it has increased 1.52 % in the last trading day.

What is Nuwellis Inc (NUWE)'s business?

Nuwellis, Inc. is a commercial-stage medical technology company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.

What is the price predicton of NUWE Stock?

What is Nuwellis Inc (NUWE)'s revenue for the last quarter?

Nuwellis Inc revenue for the last quarter amounts to 2.22M USD, decreased -6.34 % YoY.

What is Nuwellis Inc (NUWE)'s earnings per share (EPS) for the last quarter?

Nuwellis Inc. EPS for the last quarter amounts to 0.56 USD, decreased -99.24 % YoY.

What changes have occurred in the market's expectations for Nuwellis Inc (NUWE)'s fundamentals?

How many employees does Nuwellis Inc (NUWE). have?

Nuwellis Inc (NUWE) has 38 emplpoyees as of January 10 2026.

What is Nuwellis Inc (NUWE) market cap?

Today NUWE has the market capitalization of 3.32M USD.